BiotechTube
Home/Acerta Pharma/Carsten Linnemann
CL

Carsten Linnemann

CEO & Vice President, Oncology Cell Therapy Development

Acerta Pharma

Therapeutic Areas

HaematologyOncology

Acerta Pharma Pipeline

DrugIndicationPhase
Acalabrutinib (CALQUENCE)B-cell malignancies (e.g., CLL, MCL, SLL)Approved/Commercial
Pipeline combinations & novel agentsHaematological malignanciesVarious (Pre-clinical to Phase 3)

Leadership Team at Acerta Pharma

LD
Lisa Drew
Head of Small Molecule Discovery
SS
Sally Sambrook
Executive Director Clinical Operations Haematology
MC
Michael Coffey
R&D Finance Director-Haematology
View full Acerta Pharma profile